Shahid Siddiqui
Overview
Explore the profile of Shahid Siddiqui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bachert C, Gevaert P, Lipworth B, Mustafa S, Lane A, Mullol J, et al.
Allergy
. 2024 Jun;
79(10):2858-2861.
PMID: 38850227
No abstract available.
2.
Peters A, Wagenmann M, Bernstein J, Khan A, Nash S, Jacob-Nara J, et al.
Allergy Asthma Proc
. 2023 Jul;
44(4):265-274.
PMID: 37480206
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease, which often coexists with allergic rhinitis (AR). Dupilumab, a fully human monoclonal antibody, blocks the shared receptor...
3.
Busse W, Pavord I, Siddiqui S, Khan A, Praestgaard A, Nash S, et al.
J Asthma Allergy
. 2023 Apr;
16:411-419.
PMID: 37096015
Purpose: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease frequently coexisting with other type 2 conditions including asthma and non-steroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD)....
4.
Papadopoulos N, Szefler S, Bacharier L, Maspero J, Domingo C, Fiocchi A, et al.
Allergy
. 2023 Apr;
78(8):2157-2167.
PMID: 37059696
Background: Cytokines, such as interleukins (IL)-4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for...
5.
Maspero J, Bachert C, Martinez F, Hanania N, Ortiz B, Patel N, et al.
J Asthma Allergy
. 2023 Apr;
16:333-342.
PMID: 37026112
Purpose: To provide a descriptive summary of clinical efficacy and health-related quality of life (HRQoL) measures in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and clinical features of obstructive...
6.
Maspero J, Khan A, Philpott C, Hellings P, Hopkins C, Wagenmann M, et al.
J Asthma Allergy
. 2023 Apr;
16:323-332.
PMID: 37016622
Purpose: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease with a high symptom burden. Data are lacking on the comparative health status of patients with...
7.
Gevaert P, Lee S, Settipane R, Wagenmann M, Msihid J, Siddiqui S, et al.
Clin Transl Immunology
. 2023 Feb;
12(1):e1433.
PMID: 36721661
Objectives: To evaluate within-patient symptom improvement in the dupilumab SINUS-24/-52 studies in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) (NCT02912468/NCT02898454). Methods: Patients received dupilumab 300 mg or placebo...
8.
Gall R, Jain N, Soong W, Settipane R, Xia C, Zhang Y, et al.
Adv Ther
. 2023 Jan;
40(3):1292-1298.
PMID: 36626107
Background: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation. In clinical studies, dupilumab reduced the...
9.
Siddiqui S, Bachert C, Chaker A, Han J, Hellings P, Peters A, et al.
ERJ Open Res
. 2022 Dec;
8(4).
PMID: 36451848
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease of the nasal and paranasal sinuses. Dupilumab is a monoclonal antibody that blocks the shared receptor component...
10.
Ge W, Wang D, Chuang C, Li Y, Rout R, Siddiqui S, et al.
Clinicoecon Outcomes Res
. 2022 Nov;
14:691-697.
PMID: 36389100
Background: Endoscopic nasal polyp (NP) surgery is a treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Previous studies report NP surgery costs of $8000-13,000 and risk of...